Kolkata, West Bengal -- (SBWIRE) -- 09/23/2013 -- Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on Federal National Mortgage Association(OTC:FNMA), AMR Corporation(PINK:AAMRQ), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).
Federal National Mortgage Association(OTC:FNMA) shares gained 6.40% and closed at $1.33. The company on Sept. 20 priced its eighth Multifamily DUS® REMIC in 2013 totaling $1.09 billion under its Fannie Mae Guaranteed Multifamily Structures (Fannie Mae GeMS™) program on September 13, 2013. All classes of FNA 2013-M12 are guaranteed by Fannie Mae with respect to the full and timely payment of interest and principal.
Additionally, the company on Sept. 4 said it is starting to prepare investors for the first transaction in which the firm would share the risk of homeowner defaults with bond buyers. Executives at Washington-based Fannie Mae (FNMA), which bought or guaranteed $468 billion of residential mortgages in the first half of the year, will discuss its credit-risk management practices on an invitation-only web conference for investors that was set to start at 12:30 p.m. today, according to an online posting.
Should Investors Buy FNMA After Yesterday’s Jump? Find Out Here
AMR Corporation(PINK:AAMRQ) shares dropped 0.76% to $3.92. The employees of American Airlines (OTCQB: AAMRQ) and US Airways (NYSE: LCC) on Sept. 18 rallied on Capitol Hill to show their support for the new American Airlines. Leading up to the rally, hundreds of pilots, flight attendants, gate agents, baggage handlers and other employees from the two companies met with more than fifty Senators and nearly 300 congressmen to make the case for the benefits of combining American Airlines and US Airways.
Additionally, the company on Sept. 9 reported August 2013 consolidated revenue and traffic results for its principal subsidiary, American Airlines, Inc., and its wholly owned subsidiary, AMR Eagle Holding Corporation. August's consolidated passenger revenue per available seat mile (PRASM) was a record high for the month, increasing an estimated 3.0 percent versus last year. Consolidated capacity and traffic were 4.2 percent and 3.2 percent higher year-over-year, respectively, resulting in a consolidated load factor of 85.0 percent, 0.8 points below the same period last year.
How Should Investors Trade AAMRQ After The Recent Volatility? Get Free Trend Analysis Here
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock jumped 2.42% to $5.93. The company on August 28 announced the completion of a Phase 1b clinical trial for APD811, an investigational oral prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). The company plans to initiate a Phase 2 clinical trial for APD811 in the first quarter of 2014.
Additionally, the company announced that data from the BELVIQ(®) (lorcaserin HCl) Phase 3 clinical trial program will be presented at the 49(th) Annual Meeting of the European Association for the Study of Diabetes (EASD) at Barcelona, Spain: September 23-27, 2013.
How Should Investors Trade ARNA After The Recent Volatility? Get Free Trend Analysis Here
Specialpennystockalert.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Specialpennystockalert.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by Specialpennystockalert.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Specialpennystockalert.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)